Why did TransDigm raise its fiscal 2024 guidance?

Management attributed the raise primarily to strong third-quarter results and improved expectations for the rest of the fiscal year, along with the inclusion of the recently acquired SEI Industries, CPI Electron Device Business, and Raptor Scientific. Net sales guidance rose $160M at the midpoint, and adjusted EPS guidance rose $0.60 at the midpoint.

How much of the growth came from acquisitions versus the core business?

Excluding SEI Industries and the CPI Electron Device Business, the third-quarter EBITDA As Defined margin was about 53.6%, versus 53.3% reported. Organic sales growth was 14.6% for the quarter against total growth of 17.3%, so acquisitions contributed roughly 2.7 points of sales growth. Raptor Scientific closed after quarter-end on July 31, 2024, so it is not in Q3 results.

Why is GAAP EPS much lower than adjusted EPS?

GAAP EPS is reduced by dividend equivalent payments made under stock option plans, which cost $1.75 per share in fiscal 2024 year to date. Adjusted EPS also excludes non-cash stock and deferred compensation expense, acquisition transaction-related expenses, and refinancing costs, net of tax effects. Investors should review both measures, since the adjustments are recurring in nature for this company.

What are the main risks from TransDigm's leverage?

Long-term debt rose to $21.4B from $19.3B at fiscal year-end 2023, and the stockholders' deficit widened to $2.5B. Quarterly interest expense was $316M, up from $291M a year earlier. The company's EBITDA As Defined covenant metrics and cash flow from operations, which was $1,473M for the first nine months, are key to servicing this debt, especially given the $2.2B spent on acquisitions in recent months.

What end markets drove the results, and what is the outlook for them?

Management said revenue improved sequentially in commercial OEM, commercial aftermarket, and defense. Fiscal 2024 guidance assumes commercial OEM revenue growth of around 20%, commercial aftermarket growth in the mid-teens, and defense growth in the high-teens. These assumptions depend on flight hours, airline profitability, and U.S. defense budgets, as noted in the company's risk factors.

TDG 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.

TransDigm Group (TDG) reported fiscal Q3 2024 results (quarter ended June 29, 2024) that were strong across the board.

Net sales rose 17.3% to $2,046 million^a, net income increased 31.0% to $461 million, and EBITDA As Defined grew 19.2% to $1,091 million, with the margin expanding to 53.3% from 52.5% a year earlier. Adjusted EPS of $9.00 was up 24% year over year. Management said revenue ran ahead of expectations and improved sequentially in all three major market channels: commercial OEM, commercial aftermarket, and defense.

Excluding the recently acquired SEI Industries and CPI Electron Device Business, the EBITDA As Defined margin was approximately 53.6%. TransDigm raised its fiscal 2024 guidance. Net sales are now expected at $7,870^b-$7,930 million, up $160 million at the midpoint.

EBITDA As Defined is now expected at $4,100^c-$4,160 million, up $85 million at the midpoint, with a margin of about 52.3%. Adjusted EPS is now expected at $32.62-$33.42, up $0.60 at the midpoint. The guidance raise reflects both the strong quarter and the contribution from acquisitions.

The company deployed over $2.2 billion^d across SEI Industries, the CPI Electron Device Business, and Raptor Scientific within roughly three months, which increases leverage and integration risk even as it supports growth. Investors should weigh the strong operating momentum against the company's heavy debt load and acquisition-driven growth. Long-term debt stood at $21.4 billion at quarter-end, and the stockholders' deficit widened to $2.5 billion.

Interest expense of $316 million in the quarter was up from $291 million a year earlier. GAAP EPS is also depressed by dividend equivalent payments tied to stock option plans, which reduced fiscal 2024 GAAP EPS by $1.75 per share. The company repriced about $997 million of Tranche J term loans and amended $2,644 million of Tranche I loans, lowering borrowing costs on that debt.

02—Key points

Key Highlights

Q3 FY2024 net sales of $2,046M, up 17.3% year over year, with organic growth of 14.6%.
Net income rose 31.0% to $461M and EPS rose 30% to $7.96; adjusted EPS of $9.00 was up 24%.
EBITDA As Defined of $1,091M grew 19.2%, and the margin expanded to 53.3% from 52.5%, about 80 basis points higher.
Fiscal 2024 guidance was raised: net sales to $7,870-$7,930M, EBITDA As Defined to $4,100-$4,160M, and adjusted EPS to $32.62-$33.42.
Acquisitions of SEI Industries, the CPI Electron Device Business, and Raptor Scientific deployed over $2.2B of capital in about three months.
Refinancing lowered the spread on about $997M of Tranche J term loans to SOFR+2.50% from SOFR+3.25%, and $2,644M of Tranche I loans were amended and extended.
Leverage remains high, with long-term debt of $21.4B and a stockholders' deficit of $2.5B at quarter-end; interest expense rose to $316M in the quarter.

03—Questions

Frequently Asked Questions

Why did TransDigm raise its fiscal 2024 guidance?
Management attributed the raise primarily to strong third-quarter results and improved expectations for the rest of the fiscal year, along with the inclusion of the recently acquired SEI Industries, CPI Electron Device Business, and Raptor Scientific. Net sales guidance rose $160M at the midpoint, and adjusted EPS guidance rose $0.60 at the midpoint.
How much of the growth came from acquisitions versus the core business?
Excluding SEI Industries and the CPI Electron Device Business, the third-quarter EBITDA As Defined margin was about 53.6%, versus 53.3% reported. Organic sales growth was 14.6% for the quarter against total growth of 17.3%, so acquisitions contributed roughly 2.7 points of sales growth. Raptor Scientific closed after quarter-end on July 31, 2024, so it is not in Q3 results.
Why is GAAP EPS much lower than adjusted EPS?
GAAP EPS is reduced by dividend equivalent payments made under stock option plans, which cost $1.75 per share in fiscal 2024 year to date. Adjusted EPS also excludes non-cash stock and deferred compensation expense, acquisition transaction-related expenses, and refinancing costs, net of tax effects. Investors should review both measures, since the adjustments are recurring in nature for this company.
What are the main risks from TransDigm's leverage?
Long-term debt rose to $21.4B from $19.3B at fiscal year-end 2023, and the stockholders' deficit widened to $2.5B. Quarterly interest expense was $316M, up from $291M a year earlier. The company's EBITDA As Defined covenant metrics and cash flow from operations, which was $1,473M for the first nine months, are key to servicing this debt, especially given the $2.2B spent on acquisitions in recent months.
What end markets drove the results, and what is the outlook for them?
Management said revenue improved sequentially in commercial OEM, commercial aftermarket, and defense. Fiscal 2024 guidance assumes commercial OEM revenue growth of around 20%, commercial aftermarket growth in the mid-teens, and defense growth in the high-teens. These assumptions depend on flight hours, airline profitability, and U.S. defense budgets, as noted in the company's risk factors.

04—Continue

← View all 8-K filings